These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33569985)

  • 41. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
    Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
    Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and Emerging Treatments for Waldenström Macroglobulinemia.
    Grimont CN; Castillo Almeida NE; Gertz MA
    Acta Haematol; 2021; 144(2):146-157. PubMed ID: 32810857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How to Sequence Therapies in Waldenström Macroglobulinemia.
    Sarosiek S; Treon SP; Castillo JJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
    Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
    Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current approach to Waldenström macroglobulinemia.
    Kapoor P; Rajkumar SV
    Blood Rev; 2023 Nov; 62():101129. PubMed ID: 37659912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.
    Gayet M; Leymarie V; Derouault P; Guérin E; Vaidié J; Pascal V; Boulin M; Dmytruk N; Chauzeix J; Trimoreau F; Gachard N; Feuillard J; Rizzo D
    Cytometry B Clin Cytom; 2022 Jan; 102(1):62-69. PubMed ID: 33634586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
    Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Talaulikar D; Joshua D; Ho PJ; Gibson J; Quach H; Gibbs S; Ling S; Ward C; Augustson BM; Trotman J; Harrison SJ; Tam CS;
    Intern Med J; 2023 Apr; 53(4):599-609. PubMed ID: 36441109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
    Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
    Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Waldenström macroglobulinemia: What a hematologist needs to know.
    Kapoor P; Paludo J; Vallumsetla N; Greipp PR
    Blood Rev; 2015 Sep; 29(5):301-19. PubMed ID: 25882617
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
    Rossi D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
    Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.